Marizyme, Inc.
MRZM · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $646 | $233 | $210 | $197 |
| % Growth | 176.6% | 11% | 6.7% | – |
| Cost of Goods Sold | $407 | $54 | $80 | $58 |
| Gross Profit | $239 | $179 | $130 | $139 |
| % Margin | 37% | 76.7% | 61.8% | 70.4% |
| R&D Expenses | $2,177 | $3,979 | $1,682 | $688 |
| G&A Expenses | $14,863 | $8,333 | $7,226 | $5,347 |
| SG&A Expenses | $17,063 | $8,333 | $7,226 | $4,659 |
| Sales & Mktg Exp. | $2,200 | $0 | $0 | $0 |
| Other Operating Expenses | $15,086 | $841 | $44 | $591 |
| Operating Expenses | $34,325 | $13,153 | $8,951 | $5,938 |
| Operating Income | -$34,087 | -$12,974 | -$8,821 | -$5,800 |
| % Margin | -5,278.1% | -5,556.6% | -4,195.1% | -2,941.9% |
| Other Income/Exp. Net | -$31,260 | -$842 | -$2,177 | -$45 |
| Pre-Tax Income | -$65,347 | -$38,166 | -$10,998 | -$5,845 |
| Tax Expense | $4,192 | $0 | $0 | $0 |
| Net Income | -$69,539 | -$38,166 | -$10,998 | -$5,845 |
| % Margin | -10,767.8% | -16,346.2% | -5,230.2% | -2,965% |
| EPS | -1.53 | -0.94 | -0.31 | -0.22 |
| % Growth | -62.8% | -203.2% | -40.9% | – |
| EPS Diluted | -1.53 | -0.94 | -0.31 | -0.22 |
| Weighted Avg Shares Out | 45,473 | 40,727 | 36,042 | 26,374 |
| Weighted Avg Shares Out Dil | 45,473 | 40,727 | 36,042 | 26,374 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,081 | $0 | $0 | $0 |
| Interest Expense | $30,224 | $2,789 | $126 | $45 |
| Depreciation & Amortization | $841 | $841 | $44 | $591 |
| EBITDA | -$55,444 | -$34,535 | -$10,828 | -$5,208 |
| % Margin | -8,585.2% | -14,791.2% | -5,149.4% | -2,641.9% |